Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios
Summary
The new entity aims to address ocular conditions related to aging, with a focus on presbyopia, cataracts, and geographic atrophy.A central component of the merged portfolio is BRIMOCHOL PF, a once-daily, presbyopia-correcting eye drop. BRIMOCHOL PF is expected to be filed for New Drug Application (NDA) approval in the first half of 2025, with plans for commercialization in the US by 2026.Henric Bjarke has been appointed CEO of the combined company. Bjarke has prior leadership experience in biopharmaceutical companies focusing on ophthalmology and other therapeutic areas.As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with BRIMOCHOL PF, a near-term therapeutic medicine for presbyopia alongside other innovative therapies to treat cataract and geographic atrophy, Bjarke said in a statement. With our combined teams, we have the right expertise to develop and successfully launch innovative products with the potential to be first and best in class in ophthalmic medicines.David Guyer, MD, will serve as Chairman of the Board.The merger of Tenpoint and Visus is a pivotal moment in the evolution of both companies, he said in a statement. As Board Chair, I am excited about the opportunity to collaborate with the new leadership team to commercialize BRIMOCHOL PF and advance innovative products into clinical development to meet unmet needs in ocular diseases,The company plans to initiate a crossover financing round to fund ongoing clinical studies and prepare for the commercialization of BRIMOCHOL PF.1According to the companies, this merger consolidates late-stage and early-stage programs aimed at ocular conditions associated with aging.